Search engine for discovering works of Art, research articles, and books related to Art and Culture
Javascript must be enabled to continue!
Reactive Cysteines in Proteins are the Dominant Reductants for Platinum(IV) Prodrug Activation in Live Cells
View through CrossRef
AbstractThe intracellular reduction of Pt(IV) prodrugs is crucial for their anticancer efficacy. However, the major components responsible for the reduction of Pt(IV) complexes within live cells remain elusive. Herein, we developed an aminoluciferin‐functionalized Pt(IV) complex, Pt‐Luc, that can be used as a bioluminescent reporter for real‐time monitoring of Pt(IV) reduction in live cancer cells by capturing immediate bioluminescent signals from the released aminoluciferin. Utilizing this powerful reporter, we found that the reduction of Pt(IV) prodrugs in live cancer cells significantly slows down when cysteine levels are reduced, while the levels of glutathione do not impact the reduction rate. Further investigation reveals that reactive cysteines in proteins, rather than small‐molecule thiols, play a primary role in reducing the Pt(IV) complex. In vivo studies reveal a substantial 63% decrease in bioluminescence from Pt‐Luc in thiol‐blocking tumors in mice, reinforcing the pivotal role of reactive cysteines in Pt(IV) reduction. This study provides valuable insights into the activation mechanisms of Pt(IV) prodrugs in live cells and in vivo, enhancing our understanding of prodrug activation beyond buffer systems or fixed cells.
Title: Reactive Cysteines in Proteins are the Dominant Reductants for Platinum(IV) Prodrug Activation in Live Cells
Description:
AbstractThe intracellular reduction of Pt(IV) prodrugs is crucial for their anticancer efficacy.
However, the major components responsible for the reduction of Pt(IV) complexes within live cells remain elusive.
Herein, we developed an aminoluciferin‐functionalized Pt(IV) complex, Pt‐Luc, that can be used as a bioluminescent reporter for real‐time monitoring of Pt(IV) reduction in live cancer cells by capturing immediate bioluminescent signals from the released aminoluciferin.
Utilizing this powerful reporter, we found that the reduction of Pt(IV) prodrugs in live cancer cells significantly slows down when cysteine levels are reduced, while the levels of glutathione do not impact the reduction rate.
Further investigation reveals that reactive cysteines in proteins, rather than small‐molecule thiols, play a primary role in reducing the Pt(IV) complex.
In vivo studies reveal a substantial 63% decrease in bioluminescence from Pt‐Luc in thiol‐blocking tumors in mice, reinforcing the pivotal role of reactive cysteines in Pt(IV) reduction.
This study provides valuable insights into the activation mechanisms of Pt(IV) prodrugs in live cells and in vivo, enhancing our understanding of prodrug activation beyond buffer systems or fixed cells.
Related Results
Synthesis and in vitro kinetic study of new mutual prodrug for colon cancer associated with constipation
Synthesis and in vitro kinetic study of new mutual prodrug for colon cancer associated with constipation
Objective: a new mutual prodrug was synthesized for colon targeting in the treatment of colon cancer associated with constipation. Methods: a new mutual prodrug was synthesized thr...
Recent Advances in Prodrug Approach over Conventional Drug Therapy
Recent Advances in Prodrug Approach over Conventional Drug Therapy
Background:
Prodrugs represent a strategically designed category of medicinal compounds
aimed at optimizing drug pharmacokinetics. By modifying the pharmacological action of the
dr...
Abstract 738: Design and synthesis of novel N10-protected pyrrolobenzodiazepine (PBD) prodrugs for use in nitroreductase-mediated GDEPT therapies
Abstract 738: Design and synthesis of novel N10-protected pyrrolobenzodiazepine (PBD) prodrugs for use in nitroreductase-mediated GDEPT therapies
Abstract
The over-expression of telomerase in cancer cells has been previously exploited for gene therapy strategies. One approach involves the use of a plasmid cont...
MARS-seq2.0: an experimental and analytical pipeline for indexed sorting combined with single-cell RNA sequencing v1
MARS-seq2.0: an experimental and analytical pipeline for indexed sorting combined with single-cell RNA sequencing v1
Human tissues comprise trillions of cells that populate a complex space of molecular phenotypes and functions and that vary in abundance by 4–9 orders of magnitude. Relying solely ...
Abstract 1066: PD-1 expressing ex-vivo cultured tumor infiltrating lymphocytes confers tumor reactivity in cervical cancer: Possible implication for adoptive cell therapy
Abstract 1066: PD-1 expressing ex-vivo cultured tumor infiltrating lymphocytes confers tumor reactivity in cervical cancer: Possible implication for adoptive cell therapy
Abstract
Adoptive cell transfer (ACT) of ex-vivo tumor-infiltrating lymphocytes (TILs) has been shown to achieve durable clinical response in cervical cancer (CC). H...
Direct Isolation of Donor-Derived Antigen - Specific T Cells and Their Adoptive Transfer for Treatment or Prophylaxis of CMV Infection Following Allogeneic Transplantation.
Direct Isolation of Donor-Derived Antigen - Specific T Cells and Their Adoptive Transfer for Treatment or Prophylaxis of CMV Infection Following Allogeneic Transplantation.
Abstract
Reactivation of CMV is a significant cause of morbidity and mortality following allogeneic hematopoietic stem cell transplantation. Available antiviral drug...
Abstract 4157: Prodrug development of Cyclo-Creatine: Enhancing permeability and reducing toxicity for HER2+ breast cancer treatment
Abstract 4157: Prodrug development of Cyclo-Creatine: Enhancing permeability and reducing toxicity for HER2+ breast cancer treatment
Abstract
HER2+ breast cancer is an aggressive subtype of cancer that often develops resistance to the current first-line therapy, Trastuzumab. In our previous work, ...
Stem cells
Stem cells
What is a stem cell? The term is a combination of ‘cell’ and ‘stem’. A cell is a major category of living thing, while a stem is a site of growth and support for something else. In...